Tags

Type your tag names separated by a space and hit enter

Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?
Curr Drug Targets. 2019; 20(13):1369-1372.CD

Abstract

Crohn's disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a substantial number of patients still require surgery for medically refractory disease or disease-related complications. Given the widespread adoption of biologic therapies for the management of patients with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at the time of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab, an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on the postoperative outcomes for CD patients exposed to ustekinumab perioperatively.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Shim HH
Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.
Ma C
Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada. Robarts Clinical Trials, Inc. London, Canada.
Kotze PG
Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada. Inflammatory Bowel Disease Outpatient Clinics, Catholic University of Paraná (PUCPR), Curitiba, Brazil.
Panaccione R
Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada.

MeSH

Clinical Trials as TopicCrohn DiseaseDigestive System Surgical ProceduresHumansPostoperative ComplicationsPreoperative PeriodSeverity of Illness IndexUstekinumab

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

31113343

Citation

Shim, Hang Hock, et al. "Pre-operative Exposure to Ustekinumab: a Risk Factor for Postoperative Complications in Crohn's Disease (CD)?" Current Drug Targets, vol. 20, no. 13, 2019, pp. 1369-1372.
Shim HH, Ma C, Kotze PG, et al. Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)? Curr Drug Targets. 2019;20(13):1369-1372.
Shim, H. H., Ma, C., Kotze, P. G., & Panaccione, R. (2019). Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)? Current Drug Targets, 20(13), 1369-1372. https://doi.org/10.2174/1389450120666190515094435
Shim HH, et al. Pre-operative Exposure to Ustekinumab: a Risk Factor for Postoperative Complications in Crohn's Disease (CD). Curr Drug Targets. 2019;20(13):1369-1372. PubMed PMID: 31113343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)? AU - Shim,Hang Hock, AU - Ma,Christopher, AU - Kotze,Paulo Gustavo, AU - Panaccione,Remo, PY - 2018/12/22/received PY - 2019/03/12/revised PY - 2019/04/19/accepted PY - 2019/5/23/pubmed PY - 2020/8/21/medline PY - 2019/5/23/entrez KW - Crohn's disease KW - Ustekinumab KW - biologic therapies KW - chronic inflammatory KW - surgery KW - vedolizumab. SP - 1369 EP - 1372 JF - Current drug targets JO - Curr Drug Targets VL - 20 IS - 13 N2 - Crohn's disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a substantial number of patients still require surgery for medically refractory disease or disease-related complications. Given the widespread adoption of biologic therapies for the management of patients with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at the time of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab, an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on the postoperative outcomes for CD patients exposed to ustekinumab perioperatively. SN - 1873-5592 UR - https://www.unboundmedicine.com/medline/citation/31113343/Pre_operative_Exposure_to_Ustekinumab:_A_Risk_Factor_for_Postoperative_Complications_in_Crohn's_Disease__CD_ DB - PRIME DP - Unbound Medicine ER -